HNHA 是组蛋白去乙酰化酶抑制剂。它通过p21诱导将细胞周期阻滞在G1/S期，抑制肿瘤生长及肿瘤新生血管形成。HNHA可能是一种有效的抗乳腺癌药物。

HNHA is an inhibitor of HDAC.

Treatment of cells with HNHA could elicite histone hyperacetylation resulting in an up-regulation of cell cycle arrest, p21 transcription, and an inhibition of HT1080 cell invasion. HNHA was able to inhibit in-vitro HDAC enzyme activity as well as proliferation of human fibrosarcoma cells (HT1080).

Several HDAC inhibitors, including MS-27-275 and a hydroxyamide-based HDAC inhibitors such as SAHA have been investigated extensively and shown to inhibit tumor growth in vivo.

926908-04-5

C17H21NO2S

303.42

DMSO:15mg/mL(49.44mM)
Ethanol:15mg/mL(49.44mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years